1. Home
  2. DAC vs AUPH Comparison

DAC vs AUPH Comparison

Compare DAC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Danaos Corporation

DAC

Danaos Corporation

HOLD

Current Price

$127.50

Market Cap

2.4B

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$17.88

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAC
AUPH
Founded
1972
1993
Country
Greece
Canada
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
DAC
AUPH
Price
$127.50
$17.88
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$112.50
$17.25
AVG Volume (30 Days)
62.9K
1.3M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
3.00%
N/A
EPS Growth
N/A
5075.00
EPS
N/A
0.25
Revenue
N/A
$283,055,000.00
Revenue This Year
N/A
$17.54
Revenue Next Year
N/A
$15.74
P/E Ratio
$4.01
$70.04
Revenue Growth
N/A
20.38
52 Week Low
$83.56
$7.29
52 Week High
$135.21
$18.40

Technical Indicators

Market Signals
Indicator
DAC
AUPH
Relative Strength Index (RSI) 46.76 73.42
Support Level $122.57 $14.60
Resistance Level $134.25 N/A
Average True Range (ATR) 3.16 0.61
MACD -0.61 0.21
Stochastic Oscillator 31.40 84.13

Price Performance

Historical Comparison
DAC
AUPH

About DAC Danaos Corporation

Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: